Alavert, Claritin, Claritin 24–Hour Allergy, Claritin Hives Relief, Children's Loratidine, Claritin Reditabs, Clear-Atadine, Dimetapp Children's ND Non-Drowsy Allergy, Non-Drowsy Allergy Relief for Kids, Tavist ND
Relief of symptoms of seasonal allergies. Management of chronic idiopathic urticaria. Management of hives.
Blocks peripheral effects of histamine released during allergic reactions. Therapeutic Effects: Decreased symptoms of allergic reactions (nasal stuffiness; red, swollen eyes; itching).
Adverse Reactions/Side Effects
CNS: confusion, drowsiness (rare), paradoxical excitation. EENT: blurred vision. GI: dry mouth, GI upset. Derm: photosensitivity, rash. Metab: weight gain.
PHYSICAL THERAPY IMPLICATIONS
Examination and Evaluation
Monitor symptoms of seasonal allergies (sneezing, rhinitis, itching eyes, cough) or chronic idiopathic urticaria (rash, hives, itching) to help document benefits of this drug in treating these disorders.
Monitor signs of increased excitation, including restlessness, agitation, and hyperactivity. Severe or problematic excitation may require a change in dose or drug.
Periodically assess body weight and other anthropometric measures (body mass index, body composition). Report a rapid or unexplained weight gain or increased body fat.
Guard against falls and trauma (hip fractures, head injury, and so forth). Implement fall- prevention strategies, especially in older adults or if balance is impaired (See Appendix E).
Causes photosensitivity; use care if administering UV treatments. Advise patient to avoid direct sunlight and use sunscreens and protective clothing. Also report any rashes and other skin reactions.
Advise patient about the risk of daytime drowsiness, confusion, and decreased attention and mental focus. Although the risk of drowsiness is considerably lower with this drug compared to traditional antihistamines, patients should use care if driving or in other activities that require quick reactions and strong concentration.
Advise patient to avoid alcohol and other CNS depressants because of the increased risk of sedation and adverse effects.
Instruct patient to report other troublesome side effects including severe or prolonged dry mouth, skin rash, or GI upset.
Absorption: Rapidly absorbed after oral administration (80%).
Protein Binding: Loratadine—97%; descarboethoxyloratadine—73–77%.
Metabolism and Excretion: Rapidly and extensively metabolized during first pass through the liver. Much is converted to descarboethoxyloratadine, an active metabolite.
Half-life: Loratadine—7.8–11 hr; descarboethoxylo-ratadine—20 hr.
Contraindicated in: Hypersensitivity; OB: Lactation.
Use Cautiously in: Patients with hepatic impairment or CCr <30 mL/min (↓ dose to 10 mg every other day); Patients receiving drugs known to affect hepatic metabolism of drugs; Geri: ↑ risk of adverse reactions; OB/Pedi: Pregnancy ...